1. Home
  2. ALMS
  3. ALMS News

Latest ALUMIS INC (ALMS) News on February 22, 2025

ACELYRIN Confirms Receipt of Unsolicited Indication of Interest from Concentra Biosciences
ALMS

GlobeNewswire

2 days ago

ACELYRIN Confirms Receipt of Unsolicited Indication of Interest from Concentra Biosciences

Alumis to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference
ALMS

GlobeNewswire

12 days ago

Alumis to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference

ALMS

MT Newswires

12 days ago

Oppenheimer Adjusts Price Target on Alumis to $26 From $32, Keeps Outperform Rating

Alumis and Acelyrin sign merger agreement
ALMS

Pharmaceutical Technology

15 days ago

Alumis and Acelyrin sign merger agreement

We're Keeping An Eye On Alumis' (NASDAQ:ALMS) Cash Burn Rate
ALMS

Simply Wall St.

15 days ago

We're Keeping An Eye On Alumis' (NASDAQ:ALMS) Cash Burn Rate

Immune drugmakers Alumis and Acelyrin to merge
ALMS

BioPharma Dive

15 days ago

Immune drugmakers Alumis and Acelyrin to merge

Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases
ALMS

GlobeNewswire

16 days ago

Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases

Alumis Strengthens Leadership Team with Key Appointments
ALMS

GlobeNewswire

25 days ago

Alumis Strengthens Leadership Team with Key Appointments

Owning 32% shares,hedge funds owners seem interested in Alumis Inc. (NASDAQ:ALMS),
ALMS

Simply Wall St.

2 months ago

Owning 32% shares,hedge funds owners seem interested in Alumis Inc. (NASDAQ:ALMS),

Alumis Announces Positive Phase 1 Data for CNS Penetrant TYK2 Inhibitor, A-005
ALMS

GlobeNewswire

2 months ago

Alumis Announces Positive Phase 1 Data for CNS Penetrant TYK2 Inhibitor, A-005

Alumis Presents Data Highlighting ESK-001’s Potential as a High-efficacy Oral Treatment for Systemic Lupus Erythematosus (SLE) at ACR Convergence 2024
ALMS

GlobeNewswire

3 months ago

Alumis Presents Data Highlighting ESK-001’s Potential as a High-efficacy Oral Treatment for Systemic Lupus Erythematosus (SLE) at ACR Convergence 2024

Alumis Reports Third Quarter 2024 Financial Results and Highlights Recent Achievements
ALMS

GlobeNewswire

3 months ago

Alumis Reports Third Quarter 2024 Financial Results and Highlights Recent Achievements

Alumis to Participate in Guggenheim's Inaugural Healthcare Innovation Conference
ALMS

GlobeNewswire

4 months ago

Alumis to Participate in Guggenheim's Inaugural Healthcare Innovation Conference

Late-Breaking Data at EADV of ESK-001, an Oral TYK2 Inhibitor for the Treatment of Psoriasis, Demonstrate Significant Responses with Sustained Increases Over 28 Weeks in Phase 2 OLE Study
ALMS

GlobeNewswire

5 months ago

Late-Breaking Data at EADV of ESK-001, an Oral TYK2 Inhibitor for the Treatment of Psoriasis, Demonstrate Significant Responses with Sustained Increases Over 28 Weeks in Phase 2 OLE Study

Alumis to Participate in Upcoming September Investor Conferences
ALMS

GlobeNewswire

6 months ago

Alumis to Participate in Upcoming September Investor Conferences

Alumis Reports Second Quarter 2024 Financial Results and Highlights Recent Development and Corporate Achievements
ALMS

GlobeNewswire

6 months ago

Alumis Reports Second Quarter 2024 Financial Results and Highlights Recent Development and Corporate Achievements

Alumis Initiates ONWARD Phase 3 Clinical Program Evaluating ESK-001, an Oral TYK2 Inhibitor, in Moderate-to-Severe Plaque Psoriasis
ALMS

GlobeNewswire

7 months ago

Alumis Initiates ONWARD Phase 3 Clinical Program Evaluating ESK-001, an Oral TYK2 Inhibitor, in Moderate-to-Severe Plaque Psoriasis

Share on Social Networks: